- /
- Supported exchanges
- / US
- / PFE.NYSE
Pfizer Inc (PFE NYSE) stock market data APIs
Pfizer Inc Financial Data Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. has strategic collaboration with Boltz, PBC to develop and deploy state-of-the-art biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pfizer Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pfizer Inc data using free add-ons & libraries
Get Pfizer Inc Fundamental Data
Pfizer Inc Fundamental data includes:
- Net Revenue: 62 785 M
- EBITDA: 24 459 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-03
- EPS/Forecast: 0.57
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pfizer Inc News
New
Earnings live: Qualcomm stock dives as memory chip shortage weighs on outlook, Alphabet boosts AI spending
The fourth quarter earnings season momentum continues this week, with results from Alphabet (GOOG, GOOGL), Amazon (AMZN), AMD (AMD), Qualcomm (QCOM), and Palantir (PLTR) highlighting the calendar. As...
Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss
Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944 (MET-097i), which ...
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Eli Lilly's (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the success of the company's GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for weight loss). That...
Biopharmaceutical Industry Set for Unprecedented Growth in 2025: Key Trends and Contributions by Global Leaders
Precedence Research According to Precedence Research, the global biopharmaceutical industry continues to experience robust growth in 2025, with the top 20 companies leading the charge in various ther...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.